GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Plandai Biotechnology Inc (OTCPK:PLPL) » Definitions » Sloan Ratio %

Plandai Biotechnology (Plandai Biotechnology) Sloan Ratio % : 0.00% (As of Jun. 2023)


View and export this data going back to . Start your Free Trial

What is Plandai Biotechnology Sloan Ratio %?

Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.

Plandai Biotechnology's Sloan Ratio for the quarter that ended in Jun. 2023 was 0.00%.

As of Jun. 2023, Plandai Biotechnology has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.


Plandai Biotechnology Sloan Ratio % Historical Data

The historical data trend for Plandai Biotechnology's Sloan Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Plandai Biotechnology Sloan Ratio % Chart

Plandai Biotechnology Annual Data
Trend Mar09 Mar10 Mar11 Jun12 Jun13 Jun14 Jun15 Jun16 Jun22 Jun23
Sloan Ratio %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -133.42 -70.79 -49.21 - -

Plandai Biotechnology Semi-Annual Data
Mar03 Mar04 Mar05 Mar06 Mar07 Mar08 Mar09 Mar10 Mar11 Jun12 Jun13 Jun14 Jun15 Jun16 Jun22 Jun23
Sloan Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -133.42 -70.79 -49.21 - -

Competitive Comparison of Plandai Biotechnology's Sloan Ratio %

For the Shell Companies subindustry, Plandai Biotechnology's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Plandai Biotechnology's Sloan Ratio % Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, Plandai Biotechnology's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where Plandai Biotechnology's Sloan Ratio % falls into.



Plandai Biotechnology Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

Plandai Biotechnology's Sloan Ratio for the fiscal year that ended in Jun. 2023 is calculated as

Sloan Ratio=(Net Income (A: Jun. 2023 )-Cash Flow from Operations (A: Jun. 2023 )
-Cash Flow from Investing (A: Jun. 2023 ))/Total Assets (A: Jun. 2023 )
=(-19.801-0
-0)/0
=%

Plandai Biotechnology's Sloan Ratio for the quarter that ended in Jun. 2023 is calculated as

Sloan Ratio=(Net Income (TTM)-Cash Flow from Operations (TTM))
-Cash Flow from Investing (TTM))/Total Assets (Q: Jun. 2023 )
=(-19.801-0
-0)/0
=%

For company reported annually, GuruFocus uses latest annual data as the TTM data. Plandai Biotechnology's Net Income for the trailing twelve months (TTM) ended in Jun. 2023 was $-19.80 Mil.
Plandai Biotechnology's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2023 was $0.00 Mil.
Plandai Biotechnology's Cash Flow from Investing for the trailing twelve months (TTM) ended in Jun. 2023 was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Plandai Biotechnology  (OTCPK:PLPL) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Jun. 2023, Plandai Biotechnology has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.


Plandai Biotechnology Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of Plandai Biotechnology's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.


Plandai Biotechnology (Plandai Biotechnology) Business Description

Traded in Other Exchanges
N/A
Address
4811 49th Street, San Diego, CA, USA, 92115
Plandai Biotechnology Inc. manufactures highly bioavailable extracts from live plant materials.
Executives
Callum Baylis-duffield director FLAT 37 ISLAND HOUSE THREE MILL LANE, LONDON ENGLAND X0 E33AF
Timothy Matula other: Former Director 175 JACKSON AVE N, SUITE 102, MINNEAPOLIS MN 55343
Brian Johnson director P.O. BOX 1594, FERNDALE WA 98248-1594
Roger Duffield director, officer: President, Secretary and CFO 2226 EASTLAKE AVENUE EAST #156, SEATTLE WA 98102
Daron Baylis Duffield director 2226 EASTLAKE AVENUE EAST #156, SEATTLE WA 98102
David Rzepnicki director 21 HORIZON DRIVE, SARATOGA SPRINGS NY 12866